Pharmacovigilance in India: A Rising Concern towards Safe Medication Use

Deep Inder, Pawan Kumar

Abstract


Pharmacovigilance deals with studying the safety and efficacy of new as well as already existing drugs with an objective to minimize the possibility of associated risk involved with drug use. Awareness regarding pharmacovigilance is rising in response to the new challenges it faces. With the modern computer aids and technology, rapid spread of information, increased communication across borders and easy access to variety of medicinal products is possible, thus increasing public expectation regarding safety of drugs in use. To meet the challenges, there is a need to plan a strategy. We need to conduct continuing medical education programs and dynamic progress of all aspects of pharmacovigilance with interdisciplinary approach by sharing information within and across the borders to improve public health and safety of humans.


Keywords


Pharmacovigilance, Health care, Adverse drug reaction.

Full Text:

PDF

References


Singh A, Bhatt P. Comparative evaluation of adverse drug reaction reporting forms for introduction of a spontaneous generic ADR form. J Pharmacol Pharmacother Jul-Sep 2012; 3(3): 228-32.

Van den Bemt PMLA, Egberts TCG, de Jong-van den Berg LTW et al. Drug-related problems in hospitalized patients. Drug Safety 2000; 22(4): 321-33.

Pal S, Dodoo A, Mantel A et al. Pharmacovigilance and safety of medicines. In: The world medicines situation 2011. Geneva: WHO, 2011.

Kim JH, Scialli AR. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci 2011; 122: 1-6.

Collins TF. History and evolution of reproductive and developmental toxicology guidelines. Curr Pharm Res 2006; 12: 1449-65.

Edwards IR. The WHO World Alliance for Patient Safety: a new challenge or an old one neglected? Drug Saf 2005; 28: 379-86.

Labadie J. Forensic pharmacovigilance and substandard or counterfeit drugs. Int J Risk Saf Med 2012; 24: 37-39.

Graham JE, Borda-Rodriguez A, Huzair F et al. Capacity for a global vaccine safety system: the perspective of national regulatory authorities. Vaccine 2012; 30: 4953-59.

Shaw D, Graeme L, Pierre D et al. Pharmacovigilance of herbal medicine. J Ethnopharmacol 2012; 140: 513-18.

WHO. WHO: Pharmacovigilance: ensuring the safe use of medicines, 2004.

Coulter D, Hill G, Pal SN et al. Global Fund and minimum requirements for national Pharmacovigilance centre. In: A practical handbook on pharmacovigilance of medicines used in treatment of tuberculosis. WHO publishers, Geneva, 2012.

Harmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008; 64(8): 743-52.

Pharmacovigilance program of India 2010. CDSCO, Ministry of Health and Family Welfare, Government of India, Nov 2010. Available from: http:// www.cdsco.nic.in/pharmacovigilance_intro.htm. Accessed on: Jul 7, 2012.

Bhati N, Khosla PP, Gupta S. Assessment of Knowledge, Attitude and Practices (KAP) of Health Professionals Towards Adverse Drug Reactions (ADRs) and Pharmacovigilance in a Tertiary Hospital of North India. Journal of Advances in Medical Research (JAMR) 2014; 1(1): 95-98.

Amrita P, Kharbanda B. Knowledge, attitude and skills of nurses of Delhi towards adverse drug reaction reporting. Indian J Pharm Pract 2012; 5: 45-51.

Ahmad A, Parimalakrishnan S, Mohanta GP et al. Incidence of adverse drug reactions with commonly prescribed drugs in tertiary care teaching hospital in India. Int J Pharm Sci 2011; 3: 79-83.

Alshakka M, Jha N, Algefri S et al. Problems and challenges faced in consumer reporting of adverse drug reactions in developing countries-A case study of Yemen, Nepal and Malaysia. Indian J Pharm Biol Res 2014; 2(3): 37-43.

Thatte U, Bhalerao S. Pharmacovigilance of ayurvedic medicines in India. Indian J Pharmacol 2008; 40(7): 10-12.

Moore N. The role of the clinical pharmacologist in the management of ADRs. Drug Saf 2001; 24: 1-7.

Biswas P. Pharmacovigilance in Asia. J Pharmacol Pharmacother 2013; 4(1): S7-19.

Biswas P, Biswas A. Setting standards for proactive pharmacovigilance in India: The way forward. Indian J Pharmacol 2007; 39: 124-28.

Twenty-second pandemic pharmacovigilance update. Pharmacovigilance update EMA/527985/ 2010.

Almenoff JS. Innovations for the future of pharmacovigilance. Drug Saf 2007; 30: 631-33.

Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under reporting of adverse drug reactions: A systematic review. Drug Saf 2009; 32: 19-31.


Refbacks

  • There are currently no refbacks.


Copyright (c)